[go: up one dir, main page]

AR068723A1 - Proteina que se une a antigenos que se une a il-23 humana y sus usos - Google Patents

Proteina que se une a antigenos que se une a il-23 humana y sus usos

Info

Publication number
AR068723A1
AR068723A1 ARP080104318A ARP080104318A AR068723A1 AR 068723 A1 AR068723 A1 AR 068723A1 AR P080104318 A ARP080104318 A AR P080104318A AR P080104318 A ARP080104318 A AR P080104318A AR 068723 A1 AR068723 A1 AR 068723A1
Authority
AR
Argentina
Prior art keywords
sec
protein
joins
antigens
human
Prior art date
Application number
ARP080104318A
Other languages
English (en)
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40378889&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR068723(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AR068723A1 publication Critical patent/AR068723A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

También se posee una célula huésped recombinante, una composicion farmacéutica y un procedimiento para tratar un paciente humano que padece inflamacion mediada por el sistema inmunitario tales como artritis reumatoide (RA). Reivindicacion 1: Una proteína que se une a antígenos que se une a IL-23 humana y que comprende la CDRH3 de la SEC. ID. N°: 3, SEC. ID. N°: 4, SEC. ID. N.°: 73, SEC. ID. N.°: 74, SEC. ID. N.°: 95 o SEC. ID. N.°: 100, o sus variantes que contienen 1 o 2 o 3 sustituciones de aminoácidos en CDRH3. Reivindicacion 2: Una proteína que se une a antígenos de acuerdo con la reivindicacion 1, en el que dicha proteína que se une a antígenos comprende las siguientes CDR: CDRH1: SEC. ID. N.°: 1, CDRH2: SEC. ID. N.°: 2, CDRH3: SEC. ID. N.°: 4, CDRL1: SEC. ID. N.°: 5, CDRL2: SEC. ID. N.°: 6, CDRL3: SEC. ID. N.°: 7.
ARP080104318A 2007-10-05 2008-10-02 Proteina que se une a antigenos que se une a il-23 humana y sus usos AR068723A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US97784107P 2007-10-05 2007-10-05

Publications (1)

Publication Number Publication Date
AR068723A1 true AR068723A1 (es) 2009-12-02

Family

ID=40378889

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080104318A AR068723A1 (es) 2007-10-05 2008-10-02 Proteina que se une a antigenos que se une a il-23 humana y sus usos

Country Status (16)

Country Link
US (2) US20090123479A1 (es)
EP (1) EP2205637A1 (es)
JP (1) JP2011501738A (es)
KR (1) KR20100097654A (es)
CN (1) CN101889026A (es)
AR (1) AR068723A1 (es)
AU (1) AU2008306850A1 (es)
BR (1) BRPI0818620A2 (es)
CA (1) CA2700758A1 (es)
CL (1) CL2008002952A1 (es)
EA (1) EA201000424A1 (es)
MX (1) MX2010003574A (es)
PE (1) PE20091342A1 (es)
TW (1) TW200930729A (es)
WO (1) WO2009043933A1 (es)
ZA (1) ZA201002275B (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2426144T3 (en) * 2007-02-23 2019-01-07 Merck Sharp & Dohme Manipulated Anti-IL-23P19 Antibodies
CA2678863A1 (en) * 2007-02-23 2008-08-28 Schering Corporation Engineered anti-il-23p19 antibodies
US8273351B2 (en) 2008-04-25 2012-09-25 Dyax Corp. Fc receptor binding proteins
MX2011002159A (es) 2008-08-27 2011-03-29 Schering Corp Formulaciones liofilizadas de anticuerpos anti-interleucina-23p19 construidos por ingenieria.
EP2414393A1 (en) * 2009-04-01 2012-02-08 Glaxo Group Limited Anti-il-23 immunoglobulins
WO2011033493A1 (en) 2009-09-21 2011-03-24 Conservatoire National des Arts et Métiers Carrier conjugates of il-23-peptides and their induced antibodies
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
MX362039B (es) 2010-11-04 2019-01-07 Boehringer Ingelheim Int Anticuerpos anti-il-23.
CN103619353B (zh) 2011-06-02 2016-01-06 戴埃克斯有限公司 Fc受体结合蛋白
KR102124758B1 (ko) 2012-05-03 2020-06-19 베링거 인겔하임 인터내셔날 게엠베하 항-ｉｌ-23ｐ19 항체
WO2014004436A2 (en) 2012-06-27 2014-01-03 Merck Sharp & Dohme Corp. Crystalline anti-human il-23 antibodies
EP2920202B1 (en) * 2012-11-19 2018-08-29 Pieris Pharmaceuticals GmbH Novel specific-binding polypeptides and uses thereof
UA117466C2 (uk) 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
EA031025B1 (ru) * 2012-12-21 2018-11-30 Сиэтл Дженетикс, Инк. Антитела против ntb-a и связанные с ними композиции и способы
AP2015008801A0 (en) 2013-03-15 2015-10-31 Amgen Inc Methods for treating crohn's disease using an anti-il23 antibody
AU2014238148A1 (en) 2013-03-15 2015-10-08 Amgen Inc. Methods for treating psoriasis using an anti-IL-23 antibody
EP3145945B1 (en) 2014-05-22 2020-07-15 Pieris Pharmaceuticals GmbH Novel specific-binding polypeptides and uses thereof
JP2017524359A (ja) 2014-07-24 2017-08-31 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｉｌ−２３ａ関連疾患の処置に有用なバイオマーカー
MX388301B (es) 2014-09-03 2025-03-19 Boehringer Ingelheim Int Il-23a y tnf-alfa orientados y compuesto y sus usos.
KR20240158362A (ko) 2015-02-04 2024-11-04 베링거 인겔하임 인터내셔날 게엠베하 염증성 질환의 치료 방법
JP6909208B2 (ja) 2015-09-17 2021-07-28 アムジェン インコーポレイテッド Ｉｌ２３経路バイオマーカーを使用するｉｌ２３アンタゴニストに対する臨床応答の予測
RU2018119732A (ru) 2015-10-30 2019-12-03 Аблинкс Нв Полипептиды против il-23
EP3387442A4 (en) * 2015-12-09 2019-05-08 Corvus Pharmaceuticals, Inc. HUMANIZED ANTI-CD73 ANTIBODIES
WO2017112536A1 (en) 2015-12-22 2017-06-29 Amgen Inc. Ccl20 as a predictor of clinical response to il23-antagonists
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
WO2018204374A1 (en) 2017-05-02 2018-11-08 Merck Sharp & Dohme Corp. Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
AU2019247511B2 (en) 2018-04-06 2025-10-16 Atyr Pharma, Inc. Compositions and methods comprising anti-NRP2 antibodies
SG11202100185VA (en) 2018-07-13 2021-02-25 Astrazeneca Collaboration Ventures Llc Treating ulcerative colitis with brazikumab
BR112021008873A8 (pt) 2018-11-07 2023-04-11 Merck Sharp & Dohme Formulação
CA3156803A1 (en) 2019-10-03 2021-04-08 Atyr Pharma, Inc. Compositions and methods comprising anti-nrp2 antibodies
KR20220143005A (ko) 2019-12-20 2022-10-24 노바록 바이오테라퓨틱스 리미티드 항-인터루킨-23 p19 항체 및 이의 사용 방법
CN113698480B (zh) * 2021-09-18 2022-07-01 东大生物技术(苏州)有限公司 一组il-23单克隆抗体及其医药用途
WO2023076998A1 (en) * 2021-10-27 2023-05-04 Atyr Pharma, Inc. COMPOSITIONS AND METHODS COMPRISING ANTI-NRP2a ANTIBODIES
CN114920830B (zh) * 2022-05-07 2023-05-16 北京大学 Vκ4-1-IgLC多肽及其用途
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
WO2025262216A1 (en) 2024-06-21 2025-12-26 Glaxosmithkline Intellectual Property Development Limited Multispecific antigen binding proteins binding to il23 and il18

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI357336B (en) * 2003-03-10 2012-02-01 Schering Corp Uses of il-23 agonists and antagonists; related re
EP1896073B1 (en) * 2005-06-30 2013-03-06 Janssen Biotech, Inc. Anti-il-23 antibodies, compositions, methods and uses
BRPI0615018A2 (pt) * 2005-08-25 2011-04-26 Lilly Co Eli anticorpos anti-il-23, ou porção de ligação de antìgeno do mesmo, composição contendo o mesmo e referido uso
EP2354160A1 (en) * 2005-08-31 2011-08-10 Schering Corporation Engineered anti-IL-23-antibodies

Also Published As

Publication number Publication date
KR20100097654A (ko) 2010-09-03
EA201000424A1 (ru) 2010-10-29
AU2008306850A1 (en) 2009-04-09
MX2010003574A (es) 2010-04-22
BRPI0818620A2 (pt) 2019-09-24
CA2700758A1 (en) 2009-04-09
JP2011501738A (ja) 2011-01-13
CL2008002952A1 (es) 2009-10-16
CN101889026A (zh) 2010-11-17
US20090123479A1 (en) 2009-05-14
US20110206686A1 (en) 2011-08-25
PE20091342A1 (es) 2009-09-16
ZA201002275B (en) 2011-06-29
TW200930729A (en) 2009-07-16
EP2205637A1 (en) 2010-07-14
WO2009043933A1 (en) 2009-04-09

Similar Documents

Publication Publication Date Title
AR068723A1 (es) Proteina que se une a antigenos que se une a il-23 humana y sus usos
PE20121579A1 (es) Proteinas de enlace al antigeno il-23 humanas
PE20090518A1 (es) Proteinas enlazantes de antigenos que enlazan al receptor de la interleucina 18 (il-18)
PE20141660A1 (es) PROTEINAS DE UNION A ANTIGENO DE TNF-ALFA CON UNION A FcRn INCREMENTADA
MX2025004236A (es) Anticuerpo anti proteina reguladora de se?ales alfa (sirpalfana)
PE20170687A1 (es) Proteinas de enlace a cd127
JP2020500538A5 (es)
PE20080181A1 (es) Anticuerpos que se unen al peptido beta-amiloide en el tratamiento de alzheimer
PE20140133A1 (es) Nuevas proteinas de union a antigenos
AR080698A1 (es) Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e
NZ603972A (en) Anti-fgfr2 antibodies
PE20210628A1 (es) Anticuerpos anti-cd73 y metodos de uso de los mismos
HRP20250666T1 (hr) Anti-pro/latentna miostatinska protutijela i njihove uporabe
RU2014146503A (ru) Белки, связывающие антиген - лиганд cd30 человека
IL259940B2 (en) Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists
ME02807B (me) HUMANI ANTIGEN-VEZUJUĆI PROTEINI KOJI SE VEZUJU ZA BETA-KLOTHO, FGF RECEPTORE l NJIHOVE KOMPLEKSE
PE20120554A1 (es) Polipeptidos y metodo de tratamiento
AR066164A1 (es) Proteinas humanas de union a antigenos del factor estimulante de colonias de megacariocitos-macrofagos(gm-csf)
RU2588467C3 (ru) Стабильные и растворимые антитела, ингибирующие vegf
PE20090768A1 (es) Metodos y composiciones para el tratamiento de enfermedades alergicas
PE20080262A1 (es) Anticuerpo humanizado contra interleuquina-18
HRP20150965T1 (hr) Anti-fgr3 protutijela i metode koje ih koriste
IL299072A (en) Antibodies and methods for using them
FI2215124T4 (fi) Antigeenia sitovat proteiinit proproteiinikonvertaasi-subtilisiini-keksiini tyypille 9 (PCSK9)
CL2013003140A1 (es) Un anticuerpo monoclonal humano aislado o fragmento de union a antigeno del mismo que se une a masp-2 humana; molecula de acido nucleico, casette de expresion, celula que la expresa, metodo de produccion, composicion que la contiene, articulo que lo contiene.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal